18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Status Terminated

Clinical Trial Summary

The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in assessing the malignant hematopoiesis in MPN within the pediatric age group, in terms of diagnosis, staging and monitoring response to therapy. As well as, evaluating FLT-PET as a novel non-invasive technique in cases with MPN and its role in comparison to the standard bone marrow biopsy with regard to disease diagnosis, assessment of disease activity, detection of transformation, monitoring of treatment response and grading of fibrosis.Furthermore, we aim to study the association of FLT-PET uptake patterns with different genetic makeup (JAK2, CALR positive, MPL, or Triple negative disease) or allele burden in cases of Pre-PMF with the ability of FLT-PET to differentiate between Pre-PMF and ET.

Although MPNs are diseases of elderly, MPN is diagnosed in younger age groups in a considerable number of cases. Since most of the available data as well as current WHO classification criteria emphases on the "average" MPN patients who range in age between 55 and 65 years. Less consistent data are available in the groups of patients presenting below this median age, such as children and younger adults which we're planning to reveal.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Essential Thrombocythemia
Myeloproliferative Disorders
Neoplasms
Polycythemia
Polycythemia Vera
Primary Myelofibrosis
Primary Myelofibrosis, Fibrotic Stage
Primary Myelofibrosis, Prefibrotic Stage
Thrombocythemia, Essential
Thrombocytosis

Clinical Trial Details

NCT number	NCT03121599
Study type	Interventional
Source	Hamad Medical Corporation
Contact
Status	Terminated
Phase	N/A
Start date	June 11, 2017
Completion date	October 16, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05558696` - A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)	Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Completed	`NCT02912884` - Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
Recruiting	`NCT02897297` - Myeloproliferative Neoplastic Diseases Observatory From Brest
Completed	`NCT01949805` - Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera	Phase 3
Completed	`NCT00666549` - Research Tissue Bank
Completed	`NCT00241241` - Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera	Phase 2
Completed	`NCT00052520` - Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Phase 1/Phase 2
Active, not recruiting	`NCT05485948` - A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU	Phase 2
Completed	`NCT01588015` - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	Phase 1
Completed	`NCT01243944` - Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)	Phase 3
Recruiting	`NCT05481151` - A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV	Phase 3
Recruiting	`NCT05031897` - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	Phase 2
Recruiting	`NCT04116502` - MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera	Phase 3
Completed	`NCT01901432` - A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera	Phase 1/Phase 2
Active, not recruiting	`NCT04262141` - IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)	Phase 2
Not yet recruiting	`NCT05566535` - Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
Active, not recruiting	`NCT04057040` - Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)	Phase 2
Completed	`NCT03907436` - The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase	N/A
Completed	`NCT01981850` - A Phase 2 Study of RO7490677 In Participants With Myelofibrosis	Phase 2